ANI Pharmaceuticals Forecasts $1B+ 2026 Revenue with 26% Growth and Rare Disease Driving 60% Sales
ANI Pharmaceuticals projects 2026 revenue exceeding $1bn, representing 26% growth versus 2025, and anticipates delivering over 39% year-over-year revenue growth this year. The rare disease franchise, led by purified Cortrophin Gel, is expected to comprise roughly 60% of total revenues, supported by strong generics cash flow.
1. ANIP Stock Rises 7% in a Week
ANI Pharmaceuticals shares climbed 7% over the past five trading sessions, reflecting growing investor confidence after management raised its full-year guidance. Trading volume surged 45% above the 30-day average as analysts revised their estimates, citing stronger than anticipated sales in both generics and branded portfolios.
2. 2026 Guidance Tops Expectations
At the 44th Annual J.P. Morgan Healthcare Conference, CEO Nikhil Lalwani unveiled guidance calling for over $1 billion in revenue for fiscal 2026, representing 26% growth year-over-year. Management also forecast EPS expansion exceeding 39% compared to 2025, driven by both top-line momentum and operating leverage in its U.S. manufacturing facilities.
3. Rare Disease Franchise Driving Momentum
ANI’s rare disease segment is now the primary growth engine, expected to account for approximately 60% of total revenues in 2026. The recent launch of purified Cortrophin Gel offers multiyear durable growth opportunities, with management targeting peak annual sales in excess of $400 million. This franchise expansion is funded by strong cash flows from the generics business, which delivered double-digit EBITDA margins in the latest quarter.